Takeda Pharmaceutical Co. (NYSE:TAK) Shares Acquired by Avantax Advisory Services Inc.

Key Points

• Avantax Advisory Services Inc. significantly increased its holdings in Takeda Pharmaceutical Co. by 941.6%, owning 114,298 shares worth $1.7 million as of their latest SEC filing.
• Takeda Pharmaceutical reported earnings per share (EPS) of $0.16 for the most recent quarter, which fell short of analyst expectations of $0.24, while revenue was $7.34 billion against a forecast of $8.02 billion.
• The company's current stock price is at $13.73, with a market capitalization of $43.67 billion and a P/E ratio of 45.75.

Avantax Advisory Services Inc. boosted its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 941.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 114,298 shares of the company's stock after acquiring an additional 103,325 shares during the period. Avantax Advisory Services Inc.'s holdings in Takeda Pharmaceutical were worth $1,700,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. American Century Companies Inc. raised its holdings in shares of Takeda Pharmaceutical by 6.0% during the 4th quarter. American Century Companies Inc. now owns 301,087 shares of the company's stock worth $3,986,000 after acquiring an additional 17,103 shares during the period. LPL Financial LLC increased its position in Takeda Pharmaceutical by 1.9% during the fourth quarter. LPL Financial LLC now owns 186,652 shares of the company's stock worth $2,471,000 after purchasing an additional 3,564 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Takeda Pharmaceutical by 94.5% during the fourth quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock worth $1,110,000 after purchasing an additional 40,721 shares during the period. Blair William & Co. IL boosted its holdings in Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after purchasing an additional 913 shares during the last quarter. Finally, Orion Portfolio Solutions LLC acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at about $172,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Up 3.3%

Shares of NYSE TAK traded up $0.45 during midday trading on Friday, reaching $14.17. 6,215,654 shares of the stock were exchanged, compared to its average volume of 4,714,807. The stock has a market capitalization of $45.09 billion, a P/E ratio of 47.23 and a beta of 0.22. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.52 and a current ratio of 1.16. The company has a 50 day simple moving average of $14.87 and a 200 day simple moving average of $14.50. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). The business had revenue of $7.34 billion during the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. As a group, equities analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.